Fortney Kristen 4

What Happened

• Kristen Fortney, Chief Executive Officer of BioAge Labs, Inc. (BIOA), received a derivative award of 330,000 shares on February 17, 2026. The filing lists the acquisition price as $0.00 (transaction code A — grant/award). This is a compensation grant, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-02-17; Filing date (accession): 2026-02-19 (filed within the normal two-business-day Form 4 window).
• Shares/units granted: 330,000 (derivative award); reported acquisition price: $0.00.
• Shares owned after the transaction: not specified in the excerpt provided.
• Footnote: The award vests 1/48th monthly, with the first tranche having vested on February 1, 2026; subsequent tranches vest on each monthly anniversary, subject to continued service.
• No sale, cashless exercise, tax-withholding, or 10b5-1 plan noted in the reported transaction.

Context

• This is a typical executive compensation grant (derivative award) that vests over four years on a monthly schedule. Such grants are common and do not by themselves indicate an immediate buy or sell signal; they reflect ongoing compensation and retention incentives.